Ionis Regains Rights To Thrombosis Candidate From Bayer

• Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced results from the Phase 2b RE-THINC ESRD study of fesomersen to reduce the production of Factor XI (FXI) for the prevention of thrombosis.

• Ionis to regain rights to fesomersen from Bayer AG (OTC: BAYRY).

• The RE-THINC ESRD study evaluated fesomersen in patients with end-stage renal disease (ESRD) on hemodialysis.

• In the study, fesomersen achieved its primary endpoint, demonstrating no increase in the incidence of the composite of major bleeding and clinically relevant non-major (CRNM) bleeding with 24 weeks of treatment.

• Related: There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%.

• Fesomersen also achieved dose-dependent and sustained median reductions in steady-state FXI levels of 53.1%, 72.2%, and 86.6% in the 40 mg, 80 mg, and 120 mg doses of fesomersen, respectively, administered once every four weeks.

• Incidences of dialysis circuit clotting and AV-access thrombosis diminished significantly with decreasing FXI levels, both of which were exploratory efficacy endpoints.

• Fesomersen showed favorable safety and tolerability.

• Price Action: IONS shares are down 2.46% at $43.40 on the last check Friday.

See more from Benzinga

• Pfizer/BioNTech Updated Omicron Adapted COVID-19 Vaccine Shows 4-Fold Higher Neutralizing Activity

• Musk Reportedly Suspends Twitter Work On Crypto Wallet, Boeing's Jeppesen Hit By Potential Ransomware Attack, Lyft Cuts Workforce: Top Stories Friday, Nov. 04

• Snoop Dogg Microwaves His Blunts Before Smoking And For Good Reason, Here's Why - Raytheon Technologies (

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.